Artwork

内容由Dr. Tony Hoang提供。所有播客内容(包括剧集、图形和播客描述)均由 Dr. Tony Hoang 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
Player FM -播客应用
使用Player FM应用程序离线!

AI Model TRTpred Revolutionizes Cancer Immunotherapies

3:41
 
分享
 

Manage episode 417551353 series 3385494
内容由Dr. Tony Hoang提供。所有播客内容(包括剧集、图形和播客描述)均由 Dr. Tony Hoang 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal

Researchers have developed an artificial intelligence (AI) model, called TRTpred, that can accurately predict tumor-killing immune cells. The AI model was trained using gene-expression profiles from 235 T cell receptors (TCRs) of patients with metastatic melanoma. The model was able to accurately identify tumor-reactive T cells with a 90% accuracy rate. The researchers further refined the selection process by applying algorithms to identify T cells with high binding strength to tumor antigens. The combination of TRTpred and the algorithmic filters, known as MixTRTpred, was validated in mice by identifying tumor-reactive T cells capable of eliminating tumors. The researchers believe this AI model has the potential to revolutionize cancer immunotherapies by offering personalized targeting of the most effective tumor-killing T cells.

--- Send in a voice message: https://podcasters.spotify.com/pod/show/tonyphoang/message
  continue reading

621集单集

Artwork
icon分享
 
Manage episode 417551353 series 3385494
内容由Dr. Tony Hoang提供。所有播客内容(包括剧集、图形和播客描述)均由 Dr. Tony Hoang 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal

Researchers have developed an artificial intelligence (AI) model, called TRTpred, that can accurately predict tumor-killing immune cells. The AI model was trained using gene-expression profiles from 235 T cell receptors (TCRs) of patients with metastatic melanoma. The model was able to accurately identify tumor-reactive T cells with a 90% accuracy rate. The researchers further refined the selection process by applying algorithms to identify T cells with high binding strength to tumor antigens. The combination of TRTpred and the algorithmic filters, known as MixTRTpred, was validated in mice by identifying tumor-reactive T cells capable of eliminating tumors. The researchers believe this AI model has the potential to revolutionize cancer immunotherapies by offering personalized targeting of the most effective tumor-killing T cells.

--- Send in a voice message: https://podcasters.spotify.com/pod/show/tonyphoang/message
  continue reading

621集单集

All episodes

×
 
Loading …

欢迎使用Player FM

Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。

 

快速参考指南